AANS Neurosurgeon | Volume 29, Number 2, 2020


Poliovirus Therapy for Recurrent Glioblastoma Has 3-Year Survival Rate of 21%

Print Friendly, PDF & Email

Phase 1 study of Duke therapy shows long-term survival benefit for a lethal cancer


A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial.

Comparatively, just 4 percent of patients at Duke with the same type of recurring brain tumors were alive at three years when undergoing the previously available standard treatment.

Click here to read more.


No upcoming events

Comments are closed.